financetom
Business
financetom
/
Business
/
What's Going On With Dragonfly Energy Shares Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Dragonfly Energy Shares Wednesday?
Oct 15, 2025 12:26 PM

Dragonfly Energy Holdings Corp. ( DFLI ) shares are trading higher Wednesday after the company announced the issuance of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its Dragonfly IntelLigence battery communication technology.

DFLI shares are powering higher on strong volume. Get the market research here.

What To Know: The USPTO has issued a Notice of Allowance for Dragonfly Energy’s latest patent application, expanding the company’s growing portfolio of U.S. intellectual property.

The newly allowed patent covers technology enabling multiple battery systems and wireless devices to communicate over a connected mesh network. Through this technology, key operating data can be shared and warning codes can be propagated even if one of the battery systems is powered down.

"This patent strengthens our Dragonfly IntelLigence platform and represents a major step forward in connected battery technology," said CEO Denis Phares.

"By giving our batteries the ability to communicate directly with one another via our Battle Born HUB product, we’re enabling a more intelligent, adaptive, and efficient energy ecosystem."

Dragonfly said the milestone expands its U.S. intellectual property portfolio and supports its goal of advancing American battery technology and manufacturing.

See Also: Nancy Pelosi And Warren Buffett Are Betting On The Same 4 Stocks—Here’s What They Know

DFLI Price Action: At the time of writing, Dragonfly shares are trading 28.76% higher at $1.97, according to data from Benzinga Pro.

This illustration was generated using artificial intelligence via Midjourney.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arvinas' Q2 Net Loss Narrows as Revenue Rises; Names Andrew Saik CFO
Arvinas' Q2 Net Loss Narrows as Revenue Rises; Names Andrew Saik CFO
Jul 30, 2024
09:22 AM EDT, 07/30/2024 (MT Newswires) -- Arvinas ( ARVN ) reported a Q2 net loss Tuesday of $0.49 per share, narrowing from a loss of $1.25 a year earlier. Analysts polled by Capital IQ expected a loss of $0.58 per share. Revenue for the quarter ended June 30 was $76.5 million, up from $54.5 million a year earlier. Analysts...
Tilray Stock Is Trading Higher Tuesday: Here's Why
Tilray Stock Is Trading Higher Tuesday: Here's Why
Jul 30, 2024
Tilray Brands Inc ( TLRY ) shares are trading higher Tuesday after the company reported better-than-expected financial results for the fourth quarter. Q4 Revenue: $229.882 million, versus estimates of $227.07 million Q4 EPS: 4 cents, versus estimates for a loss of 2 cents Total revenue was up approximately 25% on a year-over-year basis. Cannabis net revenue jumped 12% to $71.9 million in the quarter,...
Don't write off Nike, says Britain's JD Sports
Don't write off Nike, says Britain's JD Sports
Jul 30, 2024
LONDON (Reuters) - British sports and fashion retailer JD Sports, one of Nike's largest customers, gave the world's biggest sports brand by revenue a vote of confidence on Tuesday, with a senior executive saying it will be just fine. Late last month, Nike's shares plummeted after the group warned its sales would fall this year, hurt by faltering demand for...
ZYUS Life Sciences Receives
ZYUS Life Sciences Receives "No Objection Letter" from Health Canada for Trichomylin Trial
Jul 30, 2024
09:26 AM EDT, 07/30/2024 (MT Newswires) -- ZYUS Life Sciences ( ZLSCF ) , which is developing cannabinoid-based pharmaceutical drug candidates for pain management, on Tuesday said it has received a No Objection Letter (NOL) from Health Canada for a proof-of-concept (POC) trial for its lead drug candidate, Trichomylin softgel capsules. The POC trial aims to assess the preliminary efficacy...
Copyright 2023-2026 - www.financetom.com All Rights Reserved